Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

New-wave diagnostics

A new breed of high-cost diagnostics are entering a commercial and regulatory environment that isn't designed for them. Can they prosper?

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Diagnostic revenues for 2005 among the leading diagnostic companies.
Figure 2: Commercial pharmacogenomics tests by category.
Figure 3: Predicting cancer recurrence.

References

  1. 1

    Pray, L.A. Molecular Diagnostics: New Growth, New Markets (Cambridge Healthtech Advisors, Waltham, MA, 2005).

    Google Scholar 

  2. 2

    Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).

    CAS  Article  Google Scholar 

  3. 3

    van de Vijver, M. et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baker, M. New-wave diagnostics. Nat Biotechnol 24, 931–938 (2006). https://doi.org/10.1038/nbt0806-931

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing